Contact this trialFirst, we need to learn more about you.
Antisense Oligonucleotide
Del-desiran for Myotonic Dystrophy
Recruiting1 awardPhase 3
Stanford, California
This trial aims to test the effectiveness and safety of a new drug called del-desiran in treating Myotonic Dystrophy Type 1. It will be a global study involving a large number of
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service